We use cookies and other tools to enhance your experience on our website and to analyze our web traffic.
For more information about these cookies and the data collected, please refer to our Privacy Policy.

Search

death_type_1 under Clinical Data/Incident Outcomes in WSC variables
Afib=Atrial Fibrillation, Athero_HD=Atherosclerosis, CHF=Congestive Heart Failure, MI=Myocardial Infarction, Vfib=Ventricular Fibrillation, PE=Pulmonary Embolism, AD=Alzheimers Disease, UTI=Urinary Track Infection, COPD=Chronic Obstructive Pulmonary Disease, ESRD=End Stage Renal Disease
death_type_2 under Clinical Data/Incident Outcomes in WSC variables
Afib=Atrial Fibrillation, Athero_HD=Atherosclerosis, CHF=Congestive Heart Failure, MI=Myocardial Infarction, Vfib=Ventricular Fibrillation, PE=Pulmonary Embolism, AD=Alzheimers Disease, UTI=Urinary Track Infection, COPD=Chronic Obstructive Pulmonary Disease, ESRD=End Stage Renal Disease
warf1 under Medical History/Medications/SHHS1 in SHHS variables
Participant taking ORAL ANTICOAGULANTS INCLUDING WARFARIN, COUMADIN, AND ANISINDIONE within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.
hprns2 under Medical History/Medications/SHHS2 in SHHS variables
Participant taking HEPARINS within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.
warf2 under Medical History/Medications/SHHS2 in SHHS variables
Participant taking ORAL ANTICOAGULANTS INCLUDING WARFARIN, COUMADIN, AND ANISINDIONE within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.